EUVIMEDEUVIMED entdecken
Multizentrische Studie

Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers

Jessica B DiSilvestro iD, Jessica Haddad, Katina Robison, Lindsey Beffa, Jessica Laprise, Jennifer Scalia-Wilbur, Christina Raker, Melissa A Clark, Elizabeth Lokich, Erin Hofstatter, Disha Dalela, Amy Brown und 3 weitere

Journal of Women's Health · 2024

DOI: 10.1089/jwh.2023.0621 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Women's Health, 2024. Verfasst von Jessica B DiSilvestro und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics-Gynecology, Program in Women's Oncology, Women and Infants Hospital, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Genetic Testing, Mutation, Risk Reduction Behavior. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To determine the utilization of risk-reducing strategies and screening protocols for ovarian cancer in female BRCA1/2 carriers.

Methods

This study was a sub-analysis of female participants from a larger multicenter, cross-sectional survey of BRCA1/2 mutation carriers unaffected by cancer. The questionnaire was administered electronically via email at four institutions located in the northeast United States. Data were analyzed with Fisher's exact test.

Results

The survey was completed by 104 female BRCA mutation carriers. BRCA subtypes included 54.3% BRCA2, 41.0% BRCA1, and 2.9% both. The age at which patients underwent genetic testing varied 21.2% were 18-24 years, 25.0% were 25-34 years, 29.8% were 35-44 years, and 24.0% were 45 years or older. Nearly, all respondents (97.1%) reported that a provider had discussed risk-reducing surgeries. Of the 79 females who underwent genetic testing before 45 years of age, 53.2% reported that a health care provider recommended taking combined oral contraceptive pills (COCs) to reduce their risk of ovarian cancer, and, of these women, 88.1% chose to use them. COCs were offered at higher rates among women who were younger at the age of genetic testing (18-24: 86%, 25-34: 62%, 35-44: 23%; p < 0.0001). Approximately half (55.8%) of the respondents reported having been offered increased screening for possible early detection of ovarian cancer, of which 81.0% chose to undergo screening. The majority utilized a combination of transvaginal ultrasound and serum CA125 measurements. There were no differences observed in screening utilization based on BRCA mutation type.

Conclusion

In our cohort of female BRCA mutation carriers, risk-reducing surgery was offered to almost all women, whereas only half were offered risk-reducing medication and/or increased screening. Further investigation is needed to identify barriers to the utilization of risk-reducing strategies among this high-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsGenetic TestingMutationRisk Reduction BehaviorHumansFemaleAdultMiddle AgedCross-Sectional StudiesSurveys and QuestionnairesGenes, BRCA1Young AdultGenes, BRCA2Genetic Predisposition to DiseaseHeterozygoteAdolescentEarly Detection of CancerBRCA1 Protein

Stichwörter der Autor:innen

BRCAcancer screeninggenetic counselingovarian cancerrisk management

Substanzen

BRCA1 Protein

Autor:innen und Institutionen

  • Department of Obstetrics-Gynecology, Program in Women's Oncology, Women and Infants Hospital, Providence, Rhode Island, USA.
  • The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
  • The School of Public Health, Brown University, Providence, Rhode Island, USA.
  • Cancer Genetics and Prevention Program, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA.
  • Department of Medical Oncology, Hartford Healthcare Cancer Institute, Hartford, Connecticut, USA.
  • Division of Gynecologic Oncology, Maine Medical Partners, Scarborough, Maine, USA.

ORCID-Profile: Jessica B DiSilvestro

Zitieren

APA

DiSilvestro, J. B., Haddad, J., Robison, K., Beffa, L., Laprise, J., Scalia-Wilbur, J., Raker, C., Clark, M. A., Lokich, E., Hofstatter, E., Dalela, D., Brown, A., Bradford, L., Toland, M., & Stuckey, A. (2024). Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers. Journal of Women's Health. https://doi.org/10.1089/jwh.2023.0621

Vancouver

DiSilvestro JB, Haddad J, Robison K, Beffa L, Laprise J, Scalia-Wilbur J, et al. Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers. Journal of Women's Health. 2024. doi:10.1089/jwh.2023.0621

BibTeX
@article{DiSilvestro2024,
  author = {DiSilvestro, Jessica B and Haddad, Jessica and Robison, Katina and Beffa, Lindsey and Laprise, Jessica and Scalia-Wilbur, Jennifer and Raker, Christina and Clark, Melissa A and Lokich, Elizabeth and Hofstatter, Erin and Dalela, Disha and Brown, Amy and Bradford, Leslie and Toland, Maris and Stuckey, Ashley},
  title = {Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers},
  journal = {Journal of Women's Health},
  year = {2024},
  doi = {10.1089/jwh.2023.0621}
}
Kostenlos starten →